Ligand closes $739M XOMA Royalty acquisition, doubling its royalty portfolio to more than 200 assets
LGND has more than doubled off its 52-week low of $120.68.
Summary
Ligand completed its $739 million acquisition of XOMA Royalty, doubling its royalty portfolio to over 200 assets. The deal is expected to add $0.50 and $1.50 per share to 2026 and 2027 adjusted EPS, respectively. A new $125 million credit facility was also established.
Key Events · M&A and Partnerships · LGND
-
Merger Completion
The acquisition of XOMA Royalty closed with a payment of $39.00 per share in cash plus one CVR per share, representing approximately $739 million in equity value.
-
Portfolio Expansion
Seven commercial products—including VABYSMO, OJEMDA, and MIPLYFFA—and over 100 development-stage assets join the portfolio, more than doubling Ligand's royalty assets to over 200.
-
Financial Impact
Immediate accretion is expected, with the transaction adding approximately $0.50 and $1.50 per share to Ligand's projected 2026 and 2027 adjusted EPS, respectively.
-
New Credit Facility
A $125 million revolving credit facility maturing in September 2028 was established, with covenants including a maximum consolidated senior secured net leverage ratio of 2.50x (3.00x for acquisition quarters) and minimum consolidated EBITDA of $100 million, rising to $150 million after June 2027.
Analysis · LGND · Life Sciences
The acquisition of XOMA Royalty is now complete, with Ligand paying $39.00 per share in cash plus one CVR per share. Seven commercial products and over 100 development-stage assets come with the deal, more than doubling Ligand's royalty portfolio. A new $125 million revolving credit facility was also put in place, carrying financial covenants tied to leverage and EBITDA. The transaction is expected to be immediately accretive, adding $0.50 and $1.50 per share to 2026 and 2027 adjusted EPS, respectively. This transformative deal significantly expands Ligand's revenue base and pipeline, though it introduces integration risk and increased debt capacity.
At the time of this filing, LGND was trading at $309.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $120.68 to $326.63. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.